IL17A and neoplasm: IL-17-producing NCR-negative ILC3 can increase frequency in the gut of IBD patients and is involved in tumor development given the association of neutrophil recruitment that can disrupt junction proteins, such as E-cadherin and JAML, leading to epithelial permeability, and either increasing the inflammation state or promoting angiogenesis [27].